Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 741 participants.

Also called NCT02273726

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 741 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02273726
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Puerto Rico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02273726. Randomized; no masking; primary purpose treatment. Start 2015-01-15 (actual); primary completion 2018-09-19 (actual). Results posted on 2021-10-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
Condition
CKD Anemia in Stable Dialysis Patients
Intervention (Drug)
Epoetin Alfa
Intervention (Drug)
Roxadustat
Lead sponsor
Kyntra Bio (class: industry)
Collaborator
Astellas Pharma Europe B.V. (class: industry)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02273726
Content hash
ea161e1b2c7f26a6a4f30a312911cc420cdcfe4e04ea3f29b35d85d434004d34